Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Roychoudhury, Jayeeta ^a,b   Sinha, Roma ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CARBOXYFLUORESCEIN; AMPHOTERICIN B; ANTIBODY; CHOLESTEROL; CYTOKINE; GLYCOPROTEIN P; INTERLEUKIN 10; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NITRIC OXIDE; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; RHODAMINE 123; STIBOGLUCONATE SODIUM; TRANSFORMING GROWTH FACTOR BETA; 4 CARBOXYFLUORESCEIN; 4-CARBOXYFLUORESCEIN; AMINE; ANTIMONY GLUCONATE; ANTIPROTOZOAL AGENT; FLUORESCEIN DERIVATIVE; PARASITE ANTIGEN;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BAGG ALBINO MOUSE; CONTROLLED STUDY; DILUTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG RETENTION; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; MICROSCOPY; MOUSE; NONHUMAN; REINFECTION; SINGLE DRUG DOSE; SMEAR; SPLEEN CELL; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; HUMORAL IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PARASITOLOGY; SPLEEN; VISCERAL LEISHMANIASIS;

ANIMALIA; LEISHMANIA DONOVANI; MUS;

AMINES; ANIMALS; ANTIGENS, PROTOZOAN; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CELL PROLIFERATION; CYTOKINES; DRUG RESISTANCE; FLUORESCEINS; IMMUNITY, HUMORAL; IMMUNOMODULATION; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PHOSPHATIDYLCHOLINES; RHODAMINE 123; SPLEEN;

EID: 79952507478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017376     Document Type: Article

References (66)

1. Desjeux P, (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305-318.
2. Lukes J, Mauricio IL, Schönian G, Dujardin JC, Soteriadou K, et al. (2007) Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci U S A 104: 9375-9380.
3. Croft SL, Coombs GH, (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
4. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
5. Maltezou HC, (2010) Drug resistance in visceral leishmaniasis. J Biomed Biotechnol 2010.
6. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, et al. (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763-774.
7. Sundar S, Chatterjee M, (2006) Visceral leishmaniasis- current therapeutic modalities. Indian J Med Res 123: 345-352.
8. Chunge CN, Owate J, Pamba HO, Donno L, (1990) Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 84: 221-225.
9. Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, et al. (2007) Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 77: 89-94.
10. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, et al. (2008) New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 47: 1000-1006.
11. Mastroianni A, (2004) Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS. Infez Med 12: 197-204.
12. Olliaro PL, (2010) Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 23: 595-602.
13. Valiathan R, Dubey ML, Mahajan RC, Malla N, (2006) Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate. Exp Parasitol 114: 103-108.
14. Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB, (2003) The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob Agents Chemother 47: 1529-1535.
15. Kumar D, Kulshrestha A, Singh R, Salotra P, (2009) In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53: 835-838.
16. Mandal G, Sarkar A, Saha P, Singh N, Sundar S, et al. (2009) Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys 46: 86-92.
17. Frezard F, Demicheli C, Ribeiro RR, (2009) Pentavalent antimonials: new perspectives for old drugs. Molecules 14: 2317-2336.
18. Owais M, Gupta CM, (2005) Targeted drug delivery to macrophages in parasitic infections. Curr Drug Deliv 2: 311-318.
19. Alving CR, Steck EA, Chapman WL Jr, Waits VB, Hendricks LD, et al. (1978) Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A 75: 2959-2963.
20. Alving CR, Steck EA, Hanson WL, Loizeaux PS, Chapman WL Jr, et al. (1978) Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. Life Sci 22: 1021-1026.
21. Baillie AJ, Coombs GH, Dolan TF, Laurie J, (1986) Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol 38: 502-505.
22. Black CD, Watson GJ, Ward RJ, (1977) The use of Pentostam liposomes in the chemotherapy of experimental leishmaniasis. Trans R Soc Trop Med Hyg 71: 550-552.
23. Carter KC, Dolan TF, Alexander J, Baillie AJ, McColgan C, (1989) Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol 41: 87-91.
24. Hunter CA, Dolan TF, Coombs GH, Baillie AJ, (1988) Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol 40: 161-165.
25. New RR, Chance ML, Thomas SC, Peters W, (1978) Antileishmanial activity of antimonials entrapped in liposomes. Nature 272: 55-56.
26. Carter KC, Mullen AB, Sundar S, Kenney RT, (2001) Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob Agents Chemother 45: 3555-3559.
27. Afrin F, Dey T, Anam K, Ali N, (2001) Leishmanicidal activity of stearylamine-bearing liposomes in vitro. J Parasitol 87: 188-193.
28. Dey T, Anam K, Afrin F, Ali N, (2000) Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob Agents Chemother 44: 1739-1742.
29. Pal S, Ravindran R, Ali N, (2004) Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice. Antimicrob Agents Chemother 48: 3591-3593.
30. Banerjee A, Roychoudhury J, Ali N, (2008) Stearylamine-bearing cationic liposomes kill Leishmania parasites through surface exposed negatively charged phosphatidylserine. J Antimicrob Chemother 61: 103-110.
31. Banerjee A, De M, Ali N, (2008) Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol 181: 1386-1398.
32. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW, (2003) Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 6: 271-279.
33. Bhattacharyya A, Mukherjee M, Duttagupta S, (2002) Studies on stibanate unresponsive isolates of Leishmania donovani. J Biosci 27: 503-508.
34. Kang DI, Kang HK, Gwak HS, Han HK, Lim SJ, (2009) Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells. Drug Deliv 16: 261-267.
35. Mora M, Sagrista ML, Trombetta D, Bonina FP, De Pasquale A, et al. (2002) Design and characterization of liposomes containing long-chain N-acylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm Res 19: 1430-1438.
36. Mukherjee SB, Das M, Sudhandiran G, Shaha C, (2002) Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J Biol Chem 277: 24717-24727.
37. Roberts WL, Rainey PM, (1993) Antimony quantification in Leishmania by electrothermal atomic absorption spectroscopy. Anal Biochem 211: 1-6.
38. Teng S, Jekerle V, Piquette-Miller M, (2003) Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 31: 1296-1299.
39. Stauber, A L, (1956) Resistance to the Khartoum strain of Leishmania donovani. Rice Inst. Pamphlet. 45: 80-96.
40. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, et al. (2002) Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun 70: 6697-6706.
41. Ding AH, Nathan CF, Stuehr DJ, (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412.
42. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, et al. (2007) IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 179: 5592-5603.
43. Coffman RL, Lebman DA, Rothman P, (1993) Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54: 229-270.
44. Murray HW, (2005) Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol 174: 4916-4923.
45. Haldar JP, Ghose S, Saha KC, Ghose AC, (1983) Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702-707.
46. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F, (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 2935-2943.
47. Basu R, Bhaumik S, Basu JM, Naskar K, De T, et al. (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160-7171.
48. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, et al. (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324-329.
49. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP, (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-2856.
50. Padigel UM, Alexander J, Farrell JP, (2003) The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 171: 3705-3710.
51. Ranatunga D, Hedrich CM, Wang F, McVicar DW, Nowak N, et al. (2009) A human IL10 BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proc Natl Acad Sci U S A 106: 17123-17128.
52. Anderson CF, Lira R, Kamhawi S, Belkaid Y, Wynn TA, et al. (2008) IL-10 and TGF-beta control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J Immunol 180: 4090-4097.
53. Li J, Hunter CA, Farrell JP, (1999) Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 162: 974-979.
54. Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, et al. (1992) Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257: 545-548.
55. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, et al. (1997) Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 240: 793-797.
56. Ashutosh, Sundar S, Goyal N, (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143-153.
57. Webb MS, Wheeler JJ, Bally MB, Mayer LD, (1995) The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238: 147-155.
58. Kok JW, Veldman RJ, Klappe K, Koning H, Filipeanu CM, et al. (2000) Differential expression of sphingolipids in MRP1 overexpressing HT29 cells. Int J Cancer 87: 172-178.
59. Murray HW, Oca MJ, Granger AM, Schreiber RD, (1989) Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 83: 1253-1257.
60. Banerjee A, De M, Ali N, (2011) Combination therapy with paromomycin associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th-1 biased immunomodulation. Antimicrob Agents Chemother (In Press doi: 10.1128/AAC.00524-10).
61. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Banerjee S, et al. (2006) Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 50: 1788-1797.
62. Haldar AK, Yadav V, Singhal E, Bisht KK, Singh A, et al. (2010) Leishmania donovani isolates with antimony-resistant but not-sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation. PLoS Pathog 6: e1000907.
63. Iwaoka S, Nakamura T, Takano S, Tsuchiya S, Aramaki Y, (2006) Cationic liposomes induce apoptosis through p38 MAP kinase-caspase-8-Bid pathway in macrophage-like RAW264.7 cells. J Leukoc Biol 79: 184-191.
64. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B, (2004) Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med 10: 540-544.
65. Chandra D, Naik S, (2008) Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin Exp Immunol 154: 224-234.
66. Feng GJ, Goodridge HS, Harnett MM, Wei XQ, Nikolaev AV, et al. (1999) Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 163: 6403-6412.